Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ELVN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Study of Intra-articular Allocetra in Knee Osteoarthritis NCT06233474 · Osteoarthritis, Knee Allocetra, Placebo | ELVN Enlivex Therapeutics Ltd. | Phase 1/2 | Completed was active, not recruiting | 134 | Mar 15, 2026 | Registry ↗ |
| Oct 29, 2026 | A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With… NCT07905183 · Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (C… ELVN-001, TKI | ELVN Enliven Therapeutics | Phase 3 | Not yet recruiting | 450 | Dec 31, 2028 | Registry ↗ |
| Oct 13, 2026 | Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis NCT07580716 · Primary Knee Osteoarthritis Allocetra, Placebo | ELVN Enlivex Therapeutics Ltd. | Phase 2 | Recruiting | 182 | Feb 2027 | Registry ↗ |
| Apr 13, 2026 | Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis NCT06522035 · Arthritis, Psoriatic Allocetra | ELVN Enlivex Therapeutics Ltd. | Phase 1 | Terminated | 5 | Oct 20, 2025 | Registry ↗ |
| Apr 1, 2026 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia NCT05304377 · Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leu… ELVN-001 | ELVN Enliven Therapeutics | Phase 1 | Recruiting | 250 | Dec 2027 | Registry ↗ |
| Nov 19, 2025 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer ELVN-002, Trastuzumab | ELVN Enliven Therapeutics | Phase 1 | Active, not recruiting | 275 | Jan 2027 | Registry ↗ |
| Aug 19, 2025 | A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of All… NCT04612413 · Sepsis, Community-acquired Pneumonia Allocetra-OTS, Placebo | ELVN Enlivex Therapeutics Ltd. | Phase 2 | Completed | 148 | Jan 12, 2024 | Registry ↗ |
| Jul 15, 2025 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer NCT05650879 · HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metas… ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki | ELVN Enliven Therapeutics | Phase 1 | Active, not recruiting | 198 | Jul 2026 | Registry ↗ |
| Jul 1, 2025 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese… NCT06787144 · CML (Chronic Myelogenous Leukemia), Chronic Phase CML ELVN-001 | ELVN Enliven Therapeutics | Phase 1 | Recruiting | 21 | Jan 2028 | Registry ↗ |
| Mar 13, 2024 | A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy an… NCT04922957 · Covid19 ALLOCETRA-OTS, Placebo | ELVN Enlivex Therapeutics Ltd. | Phase 2 | Terminated | 12 | Apr 1, 2022 | Registry ↗ |
| Aug 18, 2021 | Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19 NCT04659304 · Covid19 Allocetra-OTS | ELVN Enlivex Therapeutics Ltd. | Phase 1 | Unknown | 18 | Sep 2022 | Registry ↗ |
| May 19, 2020 | Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS NCT03925857 · Organ Dysfunction Syndrome Sepsis Allocetra-OTS | ELVN Enlivex Therapeutics Ltd. | Phase 1 | Completed | 10 | Dec 10, 2019 | Registry ↗ |
12 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances